It’s no longer “white pills for western markets”
The BioPharma industry is now in the process of re-evaluating the old business model predicated on blockbuster medicines for mature markets. In the words of GSK’s CEO Andrew Witty there is a recognised need to diversify away from the traditional “white pills & western markets” strategy, which no longer works in the new world of healthcare provision.
With the projected growth of 1st and 2nd tier Emerging Markets (EM) based upon rising GDP healthcare expenditure, many companies are now significantly investing in these developing economies. But what are the access considerations for manufacturers?